恩度联合GP方案治疗合并肝转移的非小细胞肺癌临床价值.docVIP

精品论文 参考文献 恩度联合GP方案治疗合并肝转移的非小细胞肺癌临床价值 广西容县人民医院肿瘤血液科 广西容县 537500 【摘 要】目的 探讨恩度联合GP方案治疗合并肝转移的肺腺癌的临床价值。方法 选择患者80例，分为两组，各40例，对照组实施GP方案治疗，观察组在对照组基础上联合恩度治疗，比较两组AFP和CEA水平，及化疗2个疗程后肝肿块缩小50%，新发远处转移及治疗后肺部病灶进展比例。结果 治疗后观察组AFP和CEA水平均显著低于对照组（Plt;0.05），观察组肝肿块缩小50%比例高于对照组（Plt;0.05），新发远处转移及治疗后肺部病灶进展比例低于对照组（Plt;0.05）。结论 恩度联合GP方案治疗发生肝转移的非小细胞肺癌，能显著降低机体AFP和CEA水平，缩小肺内病灶及转移病灶大小，改善临床治疗效果。 【关键词】恩度；GP方案；肝转移；肺腺癌 The value of Endostar combined with GP regimen for liver metastases of non-small cell lung cancer Feng Shao-ying，HU Tian-lian（Department of Oncology and Hematology， Rong xian peoples Hospital of Guangxi，537500，China） [Abstract]Objective To investigate the value of Endostar combined with GP regimen for liver metastases of lung adenocarcinoma.Methods 80 cases were divided into two groups，each 40 cases，the control group were implemented with GP regimen，the observation group were used endostar treatment under the control group，then the AFP and CEA levels were compared，After two courses of chemotherapy with tumor size 50%，the proportion of new-onset of distant metastasis and the proportion of lung lesions progress after treatment were compared.Results The observation group with AFP and CEA levels were lower than control group（Plt;0.05），the observation group with liver tumor size by 50% proportion was higher than control group（Plt;0.05），disease progression ratio were lower than control group（Plt;0.05）.Conclusion Endostar combined with GP regimen for liver metastasis of non-small cell lung cancer can significantly reduce the bodys levels of AFP and CEA and reduce the lung lesions rate and metastatic lesions，so it can improve clinical outcomes. [Keywords]Endostar；GP Program；Liver Metastases；Lung Adenocarcinoma 【中图分类号】R512.6【文献标识码】A【文章编号】2096-0867（2016）-07-008-02 非小细胞型肺癌占所有临床肺癌发病率的80%以上，相对于小细胞肺癌，非小细胞肺癌肿瘤细胞分化程度较高，且分裂速度相对较慢，同时其发生远处转移的速度亦相对较晚[1]。治疗上主要根据肿瘤分期，选择手术治疗为主，化放疗为辅的方法，而针对已经发生肝转移患者则已失去手术时期，则仅能通过化疗、放疗、生物治疗等手段进行治疗[2]。鉴于初诊的非小细胞型肺癌已经有超过50% 患者发生远处转移[3]，故对于合并有远处转移的非小细胞肺癌患者以化疗为主，放疗、生物治疗等